Cuba and Algeria opened a specialized clinic to treat diabetic foot ulcers,based on Heberprot-P, a unique therapy for these diseases.
Founded by the Cuban Center for Genetic Engineering and Biotechnology, the active principle of this medicine is the epidermal growth factor.
With a proven efficacy, Heberprot-P has patents in Europe, Latin America, Asia, and the United States.
The Cubaminrex website posts that after several years of exchanges between the Algerian laboratories LAD Pharma and the Cuban biotechnology company Heber Biotec S.A., the clinic was opened, and will be assisted by Cuban health staff.
Cuban angiologist, Joseph I. Montequin, will provide assistance to Algerian patients and will also continue an entire training program,the note stresses.
In addition to representatives from both institutions, Cuban ambassador, Raul Barzaga Navas; the president of the Algerian Diabetic Association and the Deputy Director of the Cuban Center for Genetic Engineering and Biotechnology, MSc. Ernesto Lopez Mola, among others, participated in the opening ceremony.